D
페니트리움바이오
187660KOSDAQ36.5 / 100
Reference Date: 2026-10-23
Financial Score12.0 / 40
News Sentiment12.5 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 18.1% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Penitrium Bio operates as a Contract Research Organization (CRO), providing comprehensive clinical trial services to pharmaceutical companies and biotech ventures, leveraging AI and big data for digital clinical trial technologies. The company also conducts Phase IV clinical trials to monitor drug safety and efficacy post-market approval and develops oncology treatments through its biotech business.
Number of Employees
110people
Average Salary
72.6M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
16.40Industry Average 1.200.0Point
13.7x industry avg (risky)
ROE
-105.34Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
3.59Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼17.1% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼153.1% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -79.0% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (19%, downtrend)
Current 5,520Won52-week high 18,67052-week low 2,360
1-month return0.0Point
1m -18.10% (strong drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-19
- Neutral주식등의대량보유상황보고서(일반)2026-10-14